PL1685849T3 - Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego - Google Patents
Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowegoInfo
- Publication number
- PL1685849T3 PL1685849T3 PL04799810T PL04799810T PL1685849T3 PL 1685849 T3 PL1685849 T3 PL 1685849T3 PL 04799810 T PL04799810 T PL 04799810T PL 04799810 T PL04799810 T PL 04799810T PL 1685849 T3 PL1685849 T3 PL 1685849T3
- Authority
- PL
- Poland
- Prior art keywords
- pde
- inhibitors
- interstitial cystitis
- treatment
- pelvic pain
- Prior art date
Links
- 208000005615 Interstitial Cystitis Diseases 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229950001653 cilomilast Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002586 roflumilast Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003390137 | 2003-11-20 | ||
| EP04799810A EP1685849B1 (en) | 2003-11-20 | 2004-11-18 | Pde 4 inhibitors for the treatment of interstitial cystitis |
| PCT/JP2004/017521 WO2005049087A1 (ja) | 2003-11-20 | 2004-11-18 | 慢性骨盤痛症候群治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1685849T3 true PL1685849T3 (pl) | 2012-07-31 |
Family
ID=34616327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL04799810T PL1685849T3 (pl) | 2003-11-20 | 2004-11-18 | Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167450A1 (pl) |
| EP (1) | EP1685849B1 (pl) |
| JP (1) | JPWO2005049087A1 (pl) |
| AT (1) | ATE542546T1 (pl) |
| CA (1) | CA2544322C (pl) |
| ES (1) | ES2378374T3 (pl) |
| PL (1) | PL1685849T3 (pl) |
| PT (1) | PT1685849E (pl) |
| WO (1) | WO2005049087A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2623657A1 (en) * | 2005-09-29 | 2007-04-12 | Bayer Healthcare Ag | Pde inhibitors and combinations thereof for the treatment of urological disorders |
| US8426673B2 (en) | 2008-01-11 | 2013-04-23 | Astellas Pharma, Inc. | Pathological animal model for pelvic pain syndrome |
| KR20140009244A (ko) * | 2010-11-11 | 2014-01-22 | 애크런 몰레큘스 게엠베하 | 통증 치료용 화합물 및 방법 |
| US9951335B2 (en) * | 2012-04-10 | 2018-04-24 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ290266B6 (cs) | 1993-07-02 | 2002-06-12 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
| WO1996006843A1 (en) | 1994-08-29 | 1996-03-07 | Yamanouchi Pharmaceutical Co., Ltd. | Novel naphthyridine derivative and medicinal composition thereof |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| JPH11292877A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | １，４−ジ置換ピリドピラジン誘導体 |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| US6180355B1 (en) * | 1998-05-07 | 2001-01-30 | University Of Maryland, Baltimore | Method for diagnosing and treating chronic pelvic pain syndrome |
| AR029185A1 (es) * | 1999-10-25 | 2003-06-18 | Yamanouchi Pharma Co Ltd | Derivado de naftiridina |
| GB0011802D0 (en) | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
| EP1161949A1 (en) | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Use od diazepinoindoles for the treatment of chronic obstructive pulmonary disease |
| WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| KR20040010713A (ko) * | 2001-06-15 | 2004-01-31 | 야마노우치세이야쿠 가부시키가이샤 | 페닐피리딘 카보닐 피페라진 유도체 |
| US7101847B2 (en) * | 2002-10-11 | 2006-09-05 | Milkhaus Laboratory, Inc. | Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin |
-
2004
- 2004-11-18 PL PL04799810T patent/PL1685849T3/pl unknown
- 2004-11-18 PT PT04799810T patent/PT1685849E/pt unknown
- 2004-11-18 EP EP04799810A patent/EP1685849B1/en not_active Expired - Lifetime
- 2004-11-18 WO PCT/JP2004/017521 patent/WO2005049087A1/ja not_active Ceased
- 2004-11-18 ES ES04799810T patent/ES2378374T3/es not_active Expired - Lifetime
- 2004-11-18 JP JP2005515691A patent/JPWO2005049087A1/ja active Pending
- 2004-11-18 AT AT04799810T patent/ATE542546T1/de active
- 2004-11-18 US US10/580,417 patent/US20070167450A1/en not_active Abandoned
- 2004-11-18 CA CA2544322A patent/CA2544322C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2005049087A1 (ja) | 2007-06-07 |
| ATE542546T1 (de) | 2012-02-15 |
| EP1685849A1 (en) | 2006-08-02 |
| PT1685849E (pt) | 2012-02-15 |
| US20070167450A1 (en) | 2007-07-19 |
| EP1685849A4 (en) | 2008-12-31 |
| CA2544322C (en) | 2012-05-08 |
| CA2544322A1 (en) | 2005-06-02 |
| ES2378374T3 (es) | 2012-04-11 |
| WO2005049087A1 (ja) | 2005-06-02 |
| EP1685849B1 (en) | 2012-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002321105A1 (en) | Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis | |
| DE122007000056I1 (de) | Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes | |
| SI1983000T1 (sl) | Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17 | |
| WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
| ATE520663T1 (de) | Stickstoff atom enthaltenden heteroaryl- harnstoffe als inhibitoren der p38-kinase | |
| IL144144A0 (en) | Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| NO20034056L (no) | Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer | |
| PT1470120E (pt) | Derivados n-óxidos de n-fenil-2-pirimidino-amina | |
| DE60141963D1 (de) | Antitumoreffekt-verstärker | |
| WO2004073623A3 (en) | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions | |
| WO2001044247A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| ITTO20021024A1 (it) | Trattamento di superficie per componenti ferrosi. | |
| BR0116792A (pt) | Derivados de diamina de triazol substituìdos como inibidores de quinase | |
| MXPA04007391A (es) | Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes. | |
| PL368271A1 (pl) | Sposób leczenia i zapobiegania bólowi i zapaleniuglukozaminą i inhibitorem selektywnym cyklooksygenazy-2 i kompozycje je zawierające | |
| EP1685849A4 (en) | REMEDY FOR CHRONIC PELVIC PAIN SYNDROME | |
| EE200300213A (et) | SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks | |
| WO2003053365A3 (en) | Syn3 compositions and methods | |
| WO2004110373A3 (en) | Therapeutic vaccine compositions for the treatment of type 1 diabetes | |
| WO2002039958A3 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
| NO20062229L (no) | Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) | |
| ZA200308172B (en) | Use of IL-18 inhibitors for treating or preventing CNS injuries. | |
| WO2001044235A3 (en) | Agents and methods for the treatment of proliferative diseases | |
| MXPA05010800A (es) | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos. |